What amount sold does ImmunityBio, Inc. report in Form D filings?

The latest linked filings report $640.1M sold across 8 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was ImmunityBio, Inc.'s most recent SEC filing?

ImmunityBio, Inc.'s most recent Form D filing was on 2023-09-22.

How many investors does ImmunityBio, Inc. have?

The most recent Form D filing lists 3 investor(s).

What type of securities does ImmunityBio, Inc. offer?

ImmunityBio, Inc.'s SEC Form D filings indicate equity, debt offerings.

ImmunityBio, Inc.

CIK: 0001326110·Biotechnology·SAN DIEGO, CA·Corporation

Reported Sold

$640,072,732

Total Filings

Identified Offerings

Last Filed

Sep 22, 2023

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Sep 22, 2023Form D — New notice

Reported sold: $469,986,600 · Target: $469,986,600

Rule 506(b)·3 investors

Jul 22, 2022Form D — New notice

Reported sold: $10,656,035 · Target: $10,656,035

Rule 506(b)·6 investors

Aug 5, 2015Form D — New notice

Reported sold: $17,000,000 · Target: $17,000,000

Rule 506(b)·1 investor

Jul 17, 2015Form D/A — Amendment

Reported sold: $78,004,041 · Target: $78,004,041

Rule 506(b)·11 investors

Changed: Reported amount sold, Offering target, Reported investors

Jun 24, 2015Form D — New notice

Reported sold: $71,004,041 · Target: $71,004,041

Rule 506(b)·9 investors

Jan 5, 2015Form D — New notice

Reported sold: $47,495,481 · Target: $47,495,481

Rule 506(b)·1 investor

Dec 29, 2014Form D — New notice

Reported sold: $10,000,000 · Target: $10,000,000

Rule 506(b)·1 investor

Apr 17, 2014Form D — New notice

Reported sold: $6,504,875 · Target: $9,600,000

Rule 506(b)·48 investors

Oct 9, 2009Form D — New notice

Reported sold: $425,700 · Target: $500,000

Rule 506·14 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$1,545,461

Amendment Rate

11%

Latest reported sold across 8 identified offerings

$640,072,732

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Richard Gomberg

Related Person

Appears on 5 filings

Richard Kusserow

Related Person

Appears on 5 filings

Robert Rosen

Related Person

Appears on 5 filings

Steve Gorlin

Related Person

Appears on 3 filings

Patrick Soon-Shiong, M.D.

Related Person

Appears on 3 filings

Barry J. Simon, M.D.

Related Person

Appears on 3 filings

Barry Simon

Related Person

Appears on 3 filings

Henry Ji, Ph.D.

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Sep 22, 2023	New	$469,986,600	$469,986,600	3
Jul 22, 2022	New	$10,656,035	$10,656,035	6
Aug 5, 2015	New	$17,000,000	$17,000,000	1
Jul 17, 2015	Amendment	$78,004,041	$78,004,041	11
Jun 24, 2015	New	$71,004,041	$71,004,041	9
Jan 5, 2015	New	$47,495,481	$47,495,481	1
Dec 29, 2014	New	$10,000,000	$10,000,000	1
Apr 17, 2014	New	$9,600,000	$6,504,875	48
Oct 9, 2009	New	$500,000	$425,700	14

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Trellis Bioscience, Inc.

Biotechnology

Offering target: Indefinite

Filed Oct 29, 2026